CUDC-101 concentration-response screening in three anaplastic thyroid cancer cell lines
Cell-based study · Human anaplastic thyroid cancer cell lines 8505c, C-643 and SW-1736 [1]
The authors reported screening IC50 values of 0.15 μM in 8505c and 1.66 μM in both C-643 and SW-1736. These are cellular screen endpoints, not biochemical target IC50 values. Exposure duration, precise screening readout and replicate count were not specified in the acquired article; its referenced protocol was not retrieved.
| Endpoint | Reported result | Reference |
|---|---|---|
| Concentration-dependent cellular inhibition in the 8505c anaplastic thyroid cancer qHTS screen | IC50 0.15 μM | [1] |
| Concentration-dependent cellular inhibition in the C-643 anaplastic thyroid cancer qHTS screen | IC50 1.66 μM | [1] |
| Concentration-dependent cellular inhibition in the SW-1736 anaplastic thyroid cancer qHTS screen | IC50 1.66 μM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Final screening range: 0.5 nM to 46 μM
- Method
- Quantitative high-throughput concentration-response screening of NPC and MIPE pharmaceutical collections
- Vehicle
- DMSO negative control (0% inhibition); positive control defined 100% inhibition
- Reported limits
- The acquired article delegates detailed qHTS procedures to reference 6. That original was screened but full-text XML returned HTTP 500; exposure time, assay readout and replication are therefore not established here. No conditions borrowed from another experiment.
Methods and source locations
Compound reported in the paper: CUDC-101; Compound label in the paper: CUDC-101 in NPC/MIPE pharmaceutical-library screening
Applies to the named research compound in these cellular screening models; does not establish an Adooq source, tested lot, biochemical potency or clinical efficacy.
Results: qHTS identifies CUDC-101, a dual EGFR, HER2 and HDAC inhibitor (s2_2); Methods: Quantitative high-throughput drug screening
Concentration-dependent cellular inhibition in the 8505c anaplastic thyroid cancer qHTS screen: Reported qHTS concentration-response result; final compound concentrations 0.5 nM to 46 μM. DMSO negative control and tetraoctylammonium bromide positive control. No assay readout or exposure time inferred from the cited earlier protocol. — Results: qHTS identifies CUDC-101, a dual EGFR, HER2 and HDAC inhibitor (s2_2); Methods: Quantitative high-throughput drug screening
Concentration-dependent cellular inhibition in the C-643 anaplastic thyroid cancer qHTS screen: Reported qHTS concentration-response result; final compound concentrations 0.5 nM to 46 μM. DMSO negative control and tetraoctylammonium bromide positive control. No assay readout or exposure time inferred from the cited earlier protocol. — Results: qHTS identifies CUDC-101, a dual EGFR, HER2 and HDAC inhibitor (s2_2); Methods: Quantitative high-throughput drug screening
Concentration-dependent cellular inhibition in the SW-1736 anaplastic thyroid cancer qHTS screen: Reported qHTS concentration-response result; final compound concentrations 0.5 nM to 46 μM. DMSO negative control and tetraoctylammonium bromide positive control. No assay readout or exposure time inferred from the cited earlier protocol. — Results: qHTS identifies CUDC-101, a dual EGFR, HER2 and HDAC inhibitor (s2_2); Methods: Quantitative high-throughput drug screening